Camlin Fine Sciences Q4 FY26 Earnings Call Transcript Released
Camlin Fine Sciences released its Q4 FY26 earnings call transcript. Revenue was impacted by global conflicts and shipping delays, reaching ₹424 crore for the quarter and ₹1,723 crore for the year. The company reported a ₹100 crore gain from CFS Europe liquidation and expects FY27 revenue of ₹2,200-2,400 crore with 12-14% EBITDA margins. Debt stands at ₹670 crore.
The announcement provides a detailed update on financial performance, operational challenges (supply chain, raw material costs), strategic shifts (vanillin production, diphenol plant review), and future outlook. This information is material for investors to assess the company's current standing and future prospects, thus having a medium impact.
The company reported mixed results, with revenue impacted by external factors like global conflicts and shipping delays. While there were positive aspects like the gain from subsidiary liquidation and a positive outlook for certain segments, the overall financial performance was affected by these challenges, leading to a neutral sentiment.
Camlin Fine Sciences Limited has released the transcript of its conference call held on May 26, 2026, discussing the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The call featured Chairman & Managing Director Mr. Ashish Dandekar, Managing Director Mr. Nirmal Momaya, and Chief Financial Officer Mr. Santosh Parab.
During the call, the company reported that its Q4 FY26 revenue was impacted by approximately 20% due to delayed shipments, lack of ships, and increased freight times, exacerbated by global conflicts affecting raw material availability and prices. Total revenue for the quarter stood at ₹424 crore, with total revenue for the year at ₹1,723 crore. The company also noted a shift of ₹7-8 crore in revenue to discontinued operations.
The Straights business maintained market share but saw reduced revenue due to local competition and pricing pressures. The Blends business, however, demonstrated steady growth, clocking 17% growth, which would have been 18% if discontinued European business was included. The company aims for 20% growth in this segment.
Discussions also covered the transition from methyl vanillin to ethyl vanillin production, with the ethyl vanillin plant now operational and holding orders for Q1. Realizations for vanillin have improved from sub-$11 to over $12.5 in Q4 due to tariff changes. The company also expects to receive a claim of approximately ₹9 crore for duties paid.
EBITDA for the quarter was ₹21 crore (5%). The company highlighted a gain of approximately ₹100 crore booked from the liquidation of its CFS Europe subsidiary, which will eliminate an annual cash burn of ₹50-60 crore. The outlook for the next year indicates improving vanillin realizations and volumes, with the Blends business poised for higher growth, achieving over ₹100 crore in global business in the first month of the new fiscal year.
An unfortunate incident occurred at the Dahej plant, though contained, with insurance expected to cover losses. The company is re-evaluating the diphenol plant due to raw material price volatility and availability concerns. It has secured hydroquinone from China to support downstream operations. The company's debt stands at approximately ₹670 crore, with plans to manage repayments and explore debt for growth and working capital needs, viewing equity infusion as a last resort.
Guidance for FY2027 remains on track, with projected revenues between ₹2,200 crore to ₹2,400 crore and EBITDA margins between 12% to 14%. The company expects to maintain gross margins in Q1, with potential for a 1% fluctuation.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.